Tiziana Life Sciences PLC Warrant Expiry - Reminder (1951U)
16 January 2017 - 6:00PM
UK Regulatory
TIDMTILS
RNS Number : 1951U
Tiziana Life Sciences PLC
16 January 2017
Tiziana Life Sciences PLC
("Tiziana" or the "Company")
Warrant Expiry - Reminder
London, 16 January 2017 - The Directors of Tiziana Life Sciences
plc (AIM: TILS) ("Tiziana" or "the Company") hereby provide an
update in respect of the series "B" warrants issued to investors on
18 June 2014 ("Warrants"), in connection with a fundraising by the
Company.
The Warrants will lapse at 5.00 p.m. on 28 March 2017. If
Warrant holders wish to exercise their Warrants over ordinary
shares in the Company prior to the lapsing date, the Company's
registrar, Capita Asset Services, will need to have received the
necessary exercise notice and payment from the Warrant holder or
the Warrant holder's nominee prior to 5.00 p.m. on Tuesday 28 March
2017.
Further information relating to the Warrants, including in
relation to how to exercise the Warrants, can be obtained by
emailing: info@tizianalifesciences.com or contacting Tiziana via
the Company website: www.tizianalifesciences.com. A copy of this
notice will be sent to the registered holders of the Warrants
shortly.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that
focuses on the discovery and development of novel molecules that
treat human disease in oncology and immunology.
The Company is focused on its lead compound, milciclib, a
molecule which blocks the action of specific enzymes called
cyclin-dependent kinases (CDK) involved in cell division as well as
a number of other protein kinases. Milciclib is currently
completing phase II clinical trials for epithelial thymic carcinoma
and/or thymoma in patients previously treated with chemotherapy and
has filed an IND to enroll patients in an exploratory trial in
Hepatic Cellular Carcinoma (HCC).
The Company is also in clinical development of foralumab.
Foralumab is the only fully human engineered anti-human CD3
antibody in clinical development. This phase II compound has
potential application in a wide range of autoimmune and
inflammatory diseases, such as ulcerative colitis, multiple
sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD),
psoriasis and rheumatoid arthritis, where modulation of a T-cell
response is desirable.
Tiziana Life Sciences' clinical development teams are working on
its Bcl-3 candidate; which has a prominent role in the metastasis
of mammary cancers, and has elucidated the mechanism of Bcl-3
action to be a regulator of cancer cell motility and has also
determined that Bcl-3 inhibition suppresses cell motility in
triple-negative, HER-2-positive PR- and ER-positive breast cancer
sub-types, suggesting that Bcl-3 may be a master regulator of this
metastatic property not only in aggressive breast cancers, but
across the clinical spectrum of breast disease. The Company is
preparing the IND package with the intention of progressing to
clinical trials early 2017.
For more information go to
http://www.tizianalifesciences.com
Contacts
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder +44 (0)20 7493 2853
Cairn Financial Advisers LLP (Nominated adviser)
Liam Murray +44 (0)20 7213 0880
Beaufort Securities Limited (Broker)
Saif Janjua +44 (0)20 7382 8300
FTI Consulting
Simon Conway / Natalie Garland-Collins +44 (0)20 3727 1000
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLELLFDFFBBBV
(END) Dow Jones Newswires
January 16, 2017 02:00 ET (07:00 GMT)
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From May 2024 to Jun 2024
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Jun 2023 to Jun 2024